# Claude caffeine and sleep — review and comparison

Reviewed 2026-10-12. Original: [Claude DOCX](</home/ivanaguilera/Downloads/Caffeine and Sleep An Educational Evidence Review.docx>). All document text, tables and reference entries read. Selected consequential claims checked against original papers and official sources; this is not an exhaustive bibliography audit. The original remains unchanged.

## Assessment

Useful focused research, with more explicit uncertainty than the earlier reports, but incomplete against the first prompt. It is strongest at comparing caffeine dose/timing trials and acknowledging search limits. It still misreads a source distinction and overgeneralizes wearable results. These findings describe this document, not a general ranking of AI models or proof of which model generated it.

## What works

- Labels itself a targeted search, rather than claiming a systematic review without methods.
- Separates population safety references from personal targets and avoids a scheduled microdosing routine.
- Includes the newer Gardiner trial omitted from the earlier reports' main analyses.
- Does not treat a statistically nonsignificant result as universal safety.
- Discloses missing retrievals instead of inventing details. This is good source practice, although it leaves required work unfinished.

## Corrections and qualifications

### EFSA: the supposed final-opinion/website conflict is misleading — section D

Claude correctly notes insufficient child/adolescent evidence, but omits the next sentence of the final abstract: adult-derived 3 mg/kg values may serve as a basis for these groups. Consequently, this figure is not confined to the draft, and its appearance on EFSA's website does not establish a contradiction. Preserve both the evidence limitation and the extrapolation. This is not a personal recommendation for a child. [Final EFSA opinion](https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2015.4102).

The report also leaves the 100-mg sleep statement unresolved. EFSA's official summary explicitly says that this amount can affect sleep in some adults near bedtime. That verifies the authority's summary; the accessible journal page contains the abstract and references rather than the full opinion's corresponding passage. [EFSA caffeine summary](https://www.efsa.europa.eu/en/topics/topic/caffeine).

### Gardiner: strong comparison, but a relevant protocol detail is missing — section B

The 23 men also received their habitual caffeine amount in a capsule within an hour of waking each intervention day. Thus, 100/400 mg describes the additional experimental dose, not necessarily total daily caffeine. The paper says habitual intake was moderate, not simply low.

The sample, test times, partial polysomnography, null finding at 100 mg, and publication dating are broadly accurate. Different test times alone do not make quantitative synthesis impossible; these two trials should not be naively averaged, but an appropriately designed synthesis could account for dose, timing and methods. [Original Gardiner paper](https://academic.oup.com/sleep/article/48/4/zsae230/7815486).

### Drake: the 5 p.m. interpretation also appears in the paper — sections B and D

Claude calls it a press-release extrapolation. It was not a separately tested universal clock-time threshold, but the original discussion itself suggests restricting afternoon consumption to before 17:00. Attribution should recognize this as the authors' interpretation, rather than placing it solely in publicity.

At six hours, the objective sleep-duration reduction exceeded an hour; diary estimates did not detect a statistically significant reduction. “Participants generally did not notice” should specify this condition instead of implying no subjective effects at any timing. Methods used a portable monitor and diaries. [Original Drake paper](https://pmc.ncbi.nlm.nih.gov/articles/PMC3805807/).

### Wearables: REM was not uniformly the weakest estimate — section D

The cited review found device-specific differences. Fitbit Charge 4 showed the least disagreement for REM among the reviewed devices, whereas Garmin's REM sensitivity was poor. Avoid converting this into a universal claim that REM estimates were weakest. Device models, algorithms, validation populations and accuracy metrics matter. [Original JMIR review](https://mhealth.jmir.org/2024/1/e52192/).

## Missing coverage

The document explicitly did not research circadian timing, light, screens or naps. It also lacks a proper sleep-stage explanation, sufficient tolerance discussion and the requested beverage comparison table. A candid search gap does not mean evidence is unavailable.

NHLBI provides authoritative introductory material on [sleep stages](https://www.nhlbi.nih.gov/health/sleep/stages-of-sleep) and [sleep/wake regulation](https://www.nhlbi.nih.gov/health/sleep/sleep-wake-cycle). Its stage guide describes approximate cycles rather than an exact 90-minute schedule. This is an official educational source, not an original experiment.

The claimed absence of retrieved primary matcha/decaf data remains a search limitation. Those gaps were not independently audited here. Several references are incomplete, and sources should be attached to specific claims more consistently.

## Comparison with previous reports

| Document | Main contribution | Main limitation for this section |
| --- | --- | --- |
| Perplexity | Broad learning outline and practical journal | Overly simple caffeine cutoff; some mismatched citations |
| Gemini | More detailed mechanisms | Draft/final source confusion and unsupported precise routines |
| Claude | Focused trial comparison and transparent uncertainty | Incomplete sleep coverage, misleading EFSA contrast, wearable overgeneralization |

Keep Perplexity's structure, Claude's qualified trial comparison, and independently checked sources. Agreement between reports is not independent confirmation: the Claude prompt explicitly directed attention to known weaknesses and named the two trials.

See [the earlier comparison](GEMINI-PERPLEXITY-COMPARISON.md) and [the corrected working guide](WORKING-GUIDE.md). No personal health routine has been prescribed or changed.

## Follow-up prompt for the same Claude conversation

> Complete and correct your first report before starting another topic. Use web search and open the original sources. In the final EFSA 2015 opinion, read both consecutive sentences about children/adolescents; correct the claim that 3 mg/kg is confined to the draft or conflicts with the website. Check EFSA's official 100-mg sleep statement. In Gardiner's original methods, include the habitual morning caffeine capsule so experimental dose is not confused with total daily intake. In Drake's original discussion, verify the authors' own 17:00 interpretation and distinguish objective from diary findings at six hours. Correct the device-specific REM interpretation using the JMIR review. Complete the missing sleep-pressure/circadian explanation, stages and variable cycles, naps, light/screens, caffeine tolerance, and a beverage table including clearly labeled matcha/decaf uncertainty. Attach direct citations to each substantive claim, distinguish official summaries from original studies, and state any remaining retrieval limits. Do not invent a personal cutoff, intake target or treatment plan. Return a concise correction log and an updated report; preserve rather than hide unresolved uncertainty.
